|Articles|April 28, 2016

OmniComm Signs Agreement with CROMSOURCE

OmniComm announced the signing of a five-year agreement with CROMSOURCE. OmniComm’s TrialMaster EDC suite will be used for the collection of clinical data in trials spanning all clinical phases and therapeutic areas.

Read the full release here

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
September 17th 2025
Generative AI Transforms Clinical Study Report Development
September 16th 2025
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
September 16th 2025

Trending on Applied Clinical Trials Online

Generative AI Transforms Clinical Study Report Development

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success

IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

Everything to Know About FDA’s Push Towards Radical Transparency in 2025

Managing Background Therapies in the NIMBLE Phase III Trial

© 2025 MJH Life Sciences^®

All rights reserved.